245 related articles for article (PubMed ID: 19149502)
21. What are the risks and the benefits of current and emerging weight-loss medications?
Robinson JR; Niswender KD
Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
[TBL] [Abstract][Full Text] [Related]
22. [New therapeutic aspects for the control of risk factors in obesity].
Formiguera X; Sierra A
Med Clin (Barc); 2007 Apr; 128(13):508-14. PubMed ID: 17419915
[TBL] [Abstract][Full Text] [Related]
23. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
Chaput JP; St-Pierre S; Tremblay A
Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
[TBL] [Abstract][Full Text] [Related]
24. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
[No Abstract] [Full Text] [Related]
25. Obesity drug therapy.
Baretić M
Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
[TBL] [Abstract][Full Text] [Related]
26. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
27. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
28. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
29. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U
Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
[No Abstract] [Full Text] [Related]
30. Obesity, cardiovascular risk and pharmacotherapy.
Ruilope LM; Garcia-Robles R; Moreno B
Blood Press; 2002; 11(5):260-2. PubMed ID: 12458647
[No Abstract] [Full Text] [Related]
31. Long-term pharmacotherapy for obesity.
Klein S
Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of weight-reducing drugs in hypertensive patients.
Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy for obesity in menopausal women.
Samat A; Rahim A; Barnett A
Menopause Int; 2008 Jun; 14(2):57-62. PubMed ID: 18519266
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy for obesity--promise and uncertainty.
Yanovski SZ
N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
[No Abstract] [Full Text] [Related]
35. Antiobesity drugs in early pregnancy and congenital malformations in the offspring.
Källén BA
Obes Res Clin Pract; 2014; 8(6):e571-6. PubMed ID: 25434912
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy of obesity.
Finer N
Best Pract Res Clin Endocrinol Metab; 2002 Dec; 16(4):717-42. PubMed ID: 12468417
[TBL] [Abstract][Full Text] [Related]
37. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological treatment of obesity.
Mancini MC; Halpern A
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
[TBL] [Abstract][Full Text] [Related]
39. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
[No Abstract] [Full Text] [Related]
40. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
